OBM Genetics

(ISSN 2577-5790)

OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 15.0 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2022  Archive: 2021 2020 2019 2018 2017

Special Issue

Policy Issues in Prenatal and Neonatal Testing, Counseling, and Decision-Making

Submission Deadline: July 31, 2021 (Open) Submit Now

Guest Editors

Diane B. Paul, PhD, Professor Emerita

University of Massachusetts Boston, Boston, United States

Website | E-Mail

Research Interests: newborn screening; phenylketonuria (PKU); prenatal testing and counseling; history of eugenics

Ilana Löwy, PhD, Senior Researcher Emerita

1. INSERM, France

2. French National Centre for Scientific Research, France

Website | E-Mail

Research Interests: prenatal testing; material cultures of medicine; cancer risk and screening; biomedicine and gender; biomedicine in Brazil

About This Topic

Many aspects of prenatal and neonatal testing, counseling, and decision-making raise complex policy issues that are often fiercely contested and emotionally-charged. Should newborn screening expand to include all inheritable disorders detectable at birth or should it be restricted to those disorders where presymptomatic treatment is likely to significantly reduce mortality and morbidity? And which groups should be considered legitimate stakeholders in this debate? In the prenatal domain, the advent of non-invasive prenatal testing (NIPT) has converged with the increasing stigmatization of abortion and the mobilisation of disability-rights groups to provoke new political, social, and cultural challenges to the practice of pregnancy termination for fetal anomaly and also raised questions about what prospective parents should be told and by whom about the quality of life with inherited/congenital conditions. Who should counsel women and their partners after a positive prenatal diagnosis, and what kinds of information and advice should they provide? Preimplantation genetic diagnosis (PGD) avoids the issue of pregnancy termination but raises other issues related to selection for sex and against disability and the need to acquire and dispose of embryos. These are just a few of the fraught questions with which health-care providers, advocacy groups, and policy-makers are currently grappling.

For this special issue of OBM Genetics, we invite colleagues concerned with policy issues in either domain to submit original research articles, reviews, or opinion pieces. We especially welcome contributions from practitioners able to draw on their on-the-ground experiences.

Keywords

Neonatal testing; prenatal testing (PND); preimplantation genetic diagnosis (PGD); selective abortion; Non-invasive prenatal testing (NIPT); advocacy organisations; genetic counseling; disability-rights

Publication

Open Access Original Research

The Regulation of Non-Invasive Prenatal Testing (NIPT) in France: Continuity and Changes in the Development of Prenatal Testing

Received: 02 September 2021;  Published: 25 February 2022;  doi: 10.21926/obm.genet.2201149

Abstract

This article examines the regulation of the screening of fetal abnormalities in France before and after the implementation of the new technique of non-invasive prenatal testing (NIPT) in 2013. In addition, this article evaluates the effectiveness of the regulatory framework in addressing the ethical and social issues raised by this technique [...]
Open Access Short Communication

Newborn Screening in Latin America: A Window on the Evolution of Health Policy

Received: 22 August 2021;  Published: 21 January 2022;  doi: 10.21926/obm.genet.2201146

Abstract

Investigating the historical origins of a well-accepted health program across a region, such as newborn screening in Latin America, has the potential to reveal the role of historically-specific drivers in shaping national health policy. We reviewed published reports on NBS in Latin America and interviewed newborn screening experts [...]
Open Access Original Research

Would I have Wanted to Know? A Qualitative Exploration of Women’s Attitudes, Beliefs and Concerns about Non-Invasive Prenatal Testing for de novo Genetic Conditions after having a Child with a de novo Genetic Disorder

Received: 07 September 2021;  Published: 03 November 2021;  doi: 10.21926/obm.genet.2104142

Abstract

Non-invasive prenatal testing (NIPT) for a panel of 25 single gene disorders became available in Western Australia in 2020 and potentially may be able to test for panels of hundreds of disorders as is the case with reproductive carrier screening. How this information would be used by parents in a population screening model is unkno [...]
Open Access Opinion

Screening Before We Know: Radical Uncertainties in Expanded Prenatal Genetics

Received: 15 July 2021;  Published: 09 October 2021;  doi: 10.21926/obm.genet.2104140

Abstract

In this article, we discuss the radical uncertainties unleashed by expanded prenatal genetics. We show how we are now routinely screening fetuses in the absence of two essential sorts of information. At the population level, we do not have sound, unbiased data about the prevalence, penetrance, and clinical variability of most mutations. At [...]
Open Access Review

Addressing Uncertainty: The Emergence of the CRMS/CFSPID Diagnostic Category Following Newborn Screening for Cystic Fibrosis

Received: 29 July 2021;  Published: 29 September 2021;  doi: 10.21926/obm.genet.2103139

Abstract

This article uses cystic fibrosis as a case study to examine how physicians and scientists have navigated uncertainty following newborn screening. Despite the many benefits of newborn screening, including earlier diagnosis, therapeutic intervention, and a reduced diagnostic odyssey, this public health approach also comes with chall [...]
Open Access Review

Quadruple Screening in the Age of Cell-Free DNA: What are We Losing?

Received: 16 June 2021;  Published: 27 September 2021;  doi: 10.21926/obm.genet.2103138

Abstract

Cell-free DNA has emerged as the most reliable, non-invasive prenatal screening tool for fetal aneuploidies. It has come to replace the previously widely used quadruple screen offered in the second trimester of pregnancy. This change comes with improved detection for aneuploidy but also presents potential [...]
Open Access Review

Prenatal Testing – What Is It Good For? A Review and Critique

Received: 22 June 2021;  Published: 01 September 2021;  doi: 10.21926/obm.genet.2103136

Abstract

The goals of prenatal testing remain controversial and reflect competing interests of public health, patient rights, disability activists, scholars, feminist critics, commercial laboratories, judiciary/legislative trends, and medical science. This paper reviews and critiques the most common justifications of prenatal testing for [...]
Open Access Opinion

Imagining Life with a Genetic Disorder: The Challenge of Evaluating Health States that Exist from Birth

Received: 29 March 2021;  Published: 14 May 2021;  doi: 10.21926/obm.genet.2102130

Abstract

This article explores difficulties encountered by those with no personal experience of a chronic disease or disability in accurately evaluating the quality of life with a condition present from birth. In most countries, cost-effectiveness analysis relies on ratings of health states by members of the general population, who must [...]
Announcement
Newsletter

TOP